| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts from ASENT 2005 Annual Meeting
|
|
|
2005
|
|
3 |
p. 533-538
6 p.
|
artikel
|
| 2 |
Abstracts from the ASENT 2005 Annual Meeting March 3–5, 2005
|
Houston, J. P.
|
|
2005
|
|
3 |
p. 533-538
|
artikel
|
| 3 |
Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006
|
Pritchett, Y.
|
|
2006
|
|
3 |
p. 407-415
|
artikel
|
| 4 |
An Analysis of Correlations Among 4 Outcome Scales Employed in Clinical Trials of Patients With Major Depressive Disorder
|
Jiang, Q.
|
|
2006
|
|
3 |
p. 411-412
2 p.
|
artikel
|
| 5 |
Androstenol (5α-androst-16-en-3α-ol) Is a Novel Neurosteroid Positive Modulator of GABAA Receptors: In Vitro and In Vivo Studies
|
Kaminski, R.M.
|
|
2006
|
|
3 |
p. 413-414
2 p.
|
artikel
|
| 6 |
Animal models of focal dystonia
|
Evinger, Craig
|
|
2005
|
|
3 |
p. 513-524
|
artikel
|
| 7 |
Animal Models of Focal Dystonia
|
Evinger, Craig
|
|
2005
|
|
3 |
p. 513-524
12 p.
|
artikel
|
| 8 |
Animal models of generalized dystonia
|
Raike, Robert S.
|
|
2005
|
|
3 |
p. 504-512
|
artikel
|
| 9 |
Animal Models of Generalized Dystonia
|
Raike, Robert S.
|
|
2005
|
|
3 |
p. 504-512
9 p.
|
artikel
|
| 10 |
Animal models of head trauma
|
Cernak, Ibolja
|
|
2005
|
|
3 |
p. 410-422
|
artikel
|
| 11 |
Animal Models of Head Trauma
|
Cernak, Ibolja
|
|
2005
|
|
3 |
p. 410-422
13 p.
|
artikel
|
| 12 |
Animal models of Kennedy disease
|
Merry, Diane E.
|
|
2005
|
|
3 |
p. 471-479
|
artikel
|
| 13 |
Animal Models of Kennedy Disease
|
Merry, Diane E.
|
|
2005
|
|
3 |
p. 471-479
9 p.
|
artikel
|
| 14 |
Animal models of neurological disorders
|
Chesselet, Marie-Françoise
|
|
2005
|
|
3 |
p. 395
|
artikel
|
| 15 |
Animal Models of Neurological Disorders
|
Chesselet, Marie-Françoise
|
|
2005
|
|
3 |
p. 395-
1 p.
|
artikel
|
| 16 |
Antiepileptic Drugs Do Not Affect 5-HT1A Receptor Binding Measured by Positron Emission Topography
|
Theodore, W.
|
|
2006
|
|
3 |
p. 410-
1 p.
|
artikel
|
| 17 |
Assessing the Signal Detection Properties of 3 Outcome Scales Used in Clinical Trials of Patients with Generalized Anxiety Disorder
|
Jiang, Q.
|
|
2006
|
|
3 |
p. 411-
1 p.
|
artikel
|
| 18 |
Cardiovascular Effects of Duloxetine: Preclinical and Clinical Findings
|
Detke, M.
|
|
2006
|
|
3 |
p. 407-408
2 p.
|
artikel
|
| 19 |
Characterization of Soluble Fas Receptor as a Neuroprotective Agent following Acute Spinal Cord Injury
|
Robins, S.
|
|
2006
|
|
3 |
p. 412-
1 p.
|
artikel
|
| 20 |
Crossroads in clinical trials
|
Bain, Lisa J.
|
|
2005
|
|
3 |
p. 525-528
|
artikel
|
| 21 |
Crossroads in Clinical Trials
|
Bain, Lisa J.
|
|
2005
|
|
3 |
p. 525-528
4 p.
|
artikel
|
| 22 |
CT Scan Hematoma Volume: A Surrogate Endpoint for the Effect of Treatment in Intracerebral Hemorrhage
|
Skolnick, B.E.
|
|
2006
|
|
3 |
p. 413-
1 p.
|
artikel
|
| 23 |
Development of 1-Octanol as a Novel Therapy for the Treatment of Ethanol-Responsive Essential Tremor
|
Nahab, F.
|
|
2006
|
|
3 |
p. 410-411
2 p.
|
artikel
|
| 24 |
Dose Decrease and Other Correlates of Relapse in Patients with Schizophrenia or Schizoaffective Disorder During Olanzapine Drug Therapy
|
Deberdt, W.
|
|
2006
|
|
3 |
p. 409-
1 p.
|
artikel
|
| 25 |
Drosophila models of neurodegenerative disease
|
Sang, Tzu-Kang
|
|
2005
|
|
3 |
p. 438-446
|
artikel
|
| 26 |
Drosophila Models of Neurodegenerative Disease
|
Sang, Tzu-Kang
|
|
2005
|
|
3 |
p. 438-446
9 p.
|
artikel
|
| 27 |
Duloxetine in the Management of Diabetic Peripheral Neuropathic Pain: Response Profile
|
Pritchett, Y.
|
|
2006
|
|
3 |
p. 407-
1 p.
|
artikel
|
| 28 |
Dystonia Medical Research Foundation: 30 Years of Promoting Research and Therapy Development
|
|
|
2006
|
|
3 |
p. 414-415
2 p.
|
artikel
|
| 29 |
Editorial Board
|
|
|
2006
|
|
3 |
p. i-
1 p.
|
artikel
|
| 30 |
Evaluation of Duloxetine Effectiveness in the Management of DPNP with Respect to Baseline Characteristics
|
Pritchett, Y.
|
|
2006
|
|
3 |
p. 407-
1 p.
|
artikel
|
| 31 |
Evaluation of Polyethylene Glycol as a Neuroprotective Strategy for Acute Spinal Cord Injury
|
Baptiste, D.
|
|
2006
|
|
3 |
p. 413-
1 p.
|
artikel
|
| 32 |
Evidence-based ethics for neurology and psychiatry research
|
Kim, Scott Y. H.
|
|
2004
|
|
3 |
p. 372-377
|
artikel
|
| 33 |
Evidence-Based Ethics for Neurology and Psychiatry Research
|
Kim, Scott Y.H.
|
|
2004
|
|
3 |
p. 372-377
6 p.
|
artikel
|
| 34 |
Evidence-based neurotherapeutics: A spectrum of evidence
|
Holloway, Robert G.
|
|
2004
|
|
3 |
p. 295-297
|
artikel
|
| 35 |
Evidence-Based Neurotherapeutics: A Spectrum of Evidence
|
Holloway, Robert G.
|
|
2004
|
|
3 |
p. 295-297
3 p.
|
artikel
|
| 36 |
Evidence from biomarkers and surrogate endpoints
|
Feigin, Andrew
|
|
2004
|
|
3 |
p. 323-330
|
artikel
|
| 37 |
Evidence from Biomarkers and Surrogate Endpoints
|
Feigin, Andrew
|
|
2004
|
|
3 |
p. 323-330
8 p.
|
artikel
|
| 38 |
Evidence from clinical trials: Can we do better?
|
Siderowf, Andrew D.
|
|
2004
|
|
3 |
p. 363-371
|
artikel
|
| 39 |
Evidence from Clinical Trials: Can We Do Better?
|
Siderowf, Andrew D.
|
|
2004
|
|
3 |
p. 363-371
9 p.
|
artikel
|
| 40 |
Evidence from cost-effectiveness research
|
Noyes, Katia
|
|
2004
|
|
3 |
p. 348-355
|
artikel
|
| 41 |
Evidence from Cost-Effectiveness Research
|
Noyes, Katia
|
|
2004
|
|
3 |
p. 348-355
8 p.
|
artikel
|
| 42 |
FDA: Evidentiary standards for drug development and approval
|
Katz, Russell
|
|
2004
|
|
3 |
p. 307-316
|
artikel
|
| 43 |
FDA: Evidentiary Standards for Drug Development and Approval
|
Katz, Russell
|
|
2004
|
|
3 |
p. 307-316
10 p.
|
artikel
|
| 44 |
From evidence to action
|
Gronseth, Gary S.
|
|
2004
|
|
3 |
p. 331-340
|
artikel
|
| 45 |
From Evidence to Action
|
Gronseth, Gary S.
|
|
2004
|
|
3 |
p. 331-340
10 p.
|
artikel
|
| 46 |
Funding evidence: The National Institute of Neurological Disorders and Stroke Clinical Trials Program
|
Ravina, Bernard
|
|
2004
|
|
3 |
p. 317-322
|
artikel
|
| 47 |
Funding Evidence: The National Institute of Neurological Disorders and Stroke Clinical Trials Program
|
Ravina, Bernard
|
|
2004
|
|
3 |
p. 317-322
6 p.
|
artikel
|
| 48 |
Genetic mouse models of parkinsonism: Strengths and limitations
|
Fleming, Sheila M.
|
|
2005
|
|
3 |
p. 495-503
|
artikel
|
| 49 |
Genetic Mouse Models of Parkinsonism: Strengths and Limitations
|
Fleming, Sheila M.
|
|
2005
|
|
3 |
p. 495-503
9 p.
|
artikel
|
| 50 |
Identification of a Rapid-Throughput Battery of Pheontypic Tests for Drug Candidate Evaluation in the Δ-7 Mouse Model of Spinal Muscular Atrophy
|
El-Khodor, B.
|
|
2006
|
|
3 |
p. 411-
1 p.
|
artikel
|
| 51 |
Imaging of Neurotransmitter Deficits: New Potential Biomarkers for Alzheimer’s Disease?
|
Herholz, K.
|
|
2006
|
|
3 |
p. 412-
1 p.
|
artikel
|
| 52 |
Knock-in mouse models of Huntington’s disease
|
Menalled, Liliana B.
|
|
2005
|
|
3 |
p. 465-470
|
artikel
|
| 53 |
Knock-In Mouse Models of Huntington's Disease
|
Menalled, Liliana B.
|
|
2005
|
|
3 |
p. 465-470
6 p.
|
artikel
|
| 54 |
Liquid Chromatography with Tandem Mass Spectrometry-Based Proteomic Discovery in Aging and Alzheimer’s Disease
|
Montine, Thomas J.
|
|
2006
|
|
3 |
p. 336-343
8 p.
|
artikel
|
| 55 |
Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer’s disease
|
Montine, Thomas J.
|
|
2006
|
|
3 |
p. 336-343
|
artikel
|
| 56 |
Measuring Cortical Acetylcholine Esterase Activity by PET in Dementia: Clinical Correlates
|
Herholz, K.
|
|
2006
|
|
3 |
p. 410-
1 p.
|
artikel
|
| 57 |
Microarrays in Parkinson’s disease: A systematic approach
|
Miller, Renee M.
|
|
2006
|
|
3 |
p. 319-326
|
artikel
|
| 58 |
Microarrays in Parkinson’s Disease: A Systematic Approach
|
Miller, Renee M.
|
|
2006
|
|
3 |
p. 319-326
8 p.
|
artikel
|
| 59 |
Molecular Genetics of Addiction Vulnerability
|
Uhl, George R.
|
|
2006
|
|
3 |
p. 295-301
7 p.
|
artikel
|
| 60 |
Molecular genetics of addiction vulnerability
|
Uhl, George R.
|
|
2006
|
|
3 |
p. 295-301
|
artikel
|
| 61 |
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias
|
Gould, Veronica F. Colomer
|
|
2005
|
|
3 |
p. 480-483
|
artikel
|
| 62 |
Mouse Models of Machado-Joseph Disease and Other Polyglutamine Spinocerebellar Ataxias
|
Colomer Gould, Veronica F.
|
|
2005
|
|
3 |
p. 480-483
4 p.
|
artikel
|
| 63 |
Neurosurgical Treatment of Intractable Tourette’s Syndrome: A Scientific Clinical Review of Literatures
|
Meratee, M.
|
|
2006
|
|
3 |
p. 408-
1 p.
|
artikel
|
| 64 |
NIH Countermeasures Against Chemical Threats (CounterACT) Research Program
|
Jett, D.
|
|
2006
|
|
3 |
p. 409-
1 p.
|
artikel
|
| 65 |
Noninvasive Measurement and Quantitation of Brain Iron in Parkinson’s Disease Using Adiabatic T2ρ and T1ρ High Field MRI Techniques
|
Michaeli, S.
|
|
2006
|
|
3 |
p. 408-409
2 p.
|
artikel
|
| 66 |
Observationalversus experimental studies: What’s the evidence for a hierarchy?
|
Concato, John
|
|
2004
|
|
3 |
p. 341-347
|
artikel
|
| 67 |
Observational Versus Experimental Studies: What's the Evidence for a Hierarchy?
|
Concato, John
|
|
2004
|
|
3 |
p. 341-347
7 p.
|
artikel
|
| 68 |
Policy-relevant research: When does it matter?
|
Franklin, Gary M.
|
|
2004
|
|
3 |
p. 356-362
|
artikel
|
| 69 |
Policy-Relevant Research: When Does It Matter?
|
Franklin, Gary M.
|
|
2004
|
|
3 |
p. 356-362
7 p.
|
artikel
|
| 70 |
Prediction of Combined Symptomatic and Functional Outcome in Patients with Schizophrenia or Schizoaffective Disorder
|
Lipkovich, I.
|
|
2006
|
|
3 |
p. 410-
1 p.
|
artikel
|
| 71 |
Prolonged Attenuation of Amygdla Kindled Seizures by Local Delivery of Large Molecular Weight Therapeutic Agents by Convection-Enhanced Delivery in Rats
|
Gasior, M.
|
|
2006
|
|
3 |
p. 414-
1 p.
|
artikel
|
| 72 |
Redox proteomics in some age-related neurodegenerative disorders or models thereof
|
Butterfield, D. Allan
|
|
2006
|
|
3 |
p. 344-357
|
artikel
|
| 73 |
Redox Proteomics in Some Age-Related Neurodegenerative Disorders or Models Thereof
|
Butterfield, D. Allan
|
|
2006
|
|
3 |
p. 344-357
14 p.
|
artikel
|
| 74 |
Rodent models of focal stroke: Size, mechanism, and purpose
|
Carmichael, S. Thomas
|
|
2005
|
|
3 |
p. 396-409
|
artikel
|
| 75 |
Rodent Models of Focal Stroke: Size, Mechanism, and Purpose
|
Carmichael, S. Thomas
|
|
2005
|
|
3 |
p. 396-409
14 p.
|
artikel
|
| 76 |
Single Cell Gene Expression Profiling in Alzheimer’s Disease
|
Ginsberg, Stephen D.
|
|
2006
|
|
3 |
p. 302-318
17 p.
|
artikel
|
| 77 |
Single cell gene expression profiling in Alzheimer’s disease
|
Ginsberg, Stephen D.
|
|
2006
|
|
3 |
p. 302-318
|
artikel
|
| 78 |
Speaker Abstracts from ASENT 2005 Annual Meeting
|
|
|
2005
|
|
3 |
p. 529-532
4 p.
|
artikel
|
| 79 |
Speaker abstracts from the ASENT 2005 Annual Meeting March 3–5, 2005
|
Porter, Roger J.
|
|
2005
|
|
3 |
p. 529-532
|
artikel
|
| 80 |
Survey on Patient and Physician Attitudes about Parkinson Clinical Trials
|
|
|
2006
|
|
3 |
p. 415-
1 p.
|
artikel
|
| 81 |
Systems Biology: A Primer
|
Federoff, Howard J.
|
|
2006
|
|
3 |
p. 293-294
2 p.
|
artikel
|
| 82 |
Systems biology: A primer
|
Federoff, Howard J.
|
|
2006
|
|
3 |
p. 293-294
|
artikel
|
| 83 |
The application of NMR-based metabonomics in neurological disorders
|
Holmes, Elaine
|
|
2006
|
|
3 |
p. 358-372
|
artikel
|
| 84 |
The Application of NMR-Based Metabonomics in Neurological Disorders
|
Holmes, Elaine
|
|
2006
|
|
3 |
p. 358-372
15 p.
|
artikel
|
| 85 |
The Cognitive Phenotype of Down Syndrome: Insights from Intracellular Network Analysis
|
Ma’ayan, Avi
|
|
2006
|
|
3 |
p. 396-406
11 p.
|
artikel
|
| 86 |
The cognitive phenotype of Down syndrome: Insights from intracellular network analysis
|
Ma’ayan, Avi
|
|
2006
|
|
3 |
p. 396-406
|
artikel
|
| 87 |
The Microarray Data Analysis Process: From Raw Data to Biological Significance
|
Olson, N. Eric
|
|
2006
|
|
3 |
p. 373-383
11 p.
|
artikel
|
| 88 |
The microarray data analysis process: From raw data to biological significance
|
Olson, N. Eric
|
|
2006
|
|
3 |
p. 373-383
|
artikel
|
| 89 |
The Role of Microglia and NADPH Oxidase in Traumatic Spinal Cord Injury
|
Byrnes, K.
|
|
2006
|
|
3 |
p. 408-
1 p.
|
artikel
|
| 90 |
The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies
|
Li, Jia Yi
|
|
2005
|
|
3 |
p. 447-464
|
artikel
|
| 91 |
The Use of the R6 Transgenic Mouse Models of Huntington's Disease in Attempts to Develop Novel Therapeutic Strategies
|
Li, Jia Yi
|
|
2005
|
|
3 |
p. 447-464
18 p.
|
artikel
|
| 92 |
Toxin-induced models of Parkinson’s disease
|
Bové, Jordi
|
|
2005
|
|
3 |
p. 484-494
|
artikel
|
| 93 |
Toxin-Induced Models of Parkinson's Disease
|
Bové, Jordi
|
|
2005
|
|
3 |
p. 484-494
11 p.
|
artikel
|
| 94 |
Transgenic models of Alzheimer’s disease: Learning from animals
|
Spires, Tara L.
|
|
2005
|
|
3 |
p. 423-437
|
artikel
|
| 95 |
Transgenic Models of Alzheimer's Disease: Learning from Animals
|
Spires, Tara L.
|
|
2005
|
|
3 |
p. 423-437
15 p.
|
artikel
|
| 96 |
Translating therapies for Huntington’s disease from genetic animal models to clinical trials
|
Hersch, Steven M.
|
|
2004
|
|
3 |
p. 298-306
|
artikel
|
| 97 |
Translating Therapies for Huntington's Disease from Genetic Animal Models to Clinical Trials
|
Hersch, Steven M.
|
|
2004
|
|
3 |
p. 298-306
9 p.
|
artikel
|
| 98 |
Two-dimensional Protein Electrophoresis: From Molecular Pathway Discovery to Biomarker Discovery in Neurological Disorders
|
Choe, Leila H.
|
|
2006
|
|
3 |
p. 327-335
9 p.
|
artikel
|
| 99 |
Two-dimensional protein electrophoresis: From molecular pathway discovery to biomarker discovery in neurological disorders
|
Choe, Leila H.
|
|
2006
|
|
3 |
p. 327-335
|
artikel
|
| 100 |
Utility of Correlation Measures in Analysis of Gene Expression
|
Almudevar, Anthony
|
|
2006
|
|
3 |
p. 384-395
12 p.
|
artikel
|
| 101 |
Utility of correlation measures in analysis of gene expression
|
Almudevar, Anthony
|
|
2006
|
|
3 |
p. 384-395
|
artikel
|
| 102 |
www.PDtrials.org: Increasing Parkinson’s Clinical Trial Awareness through the Internet
|
|
|
2006
|
|
3 |
p. 415-
1 p.
|
artikel
|
Tijdschrift beschrijving